| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9153701 | American Heart Journal | 2005 | 9 Pages |
Abstract
During primary angioplasty, abciximab enhances myocardial reperfusion, translating into a reduced incidence of 6-month left ventricular remodeling. In contrast, adenosine administration improves angiographic results but does not prevent left ventricular remodeling.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Anna S. MD, Marco MD, Nicola MD, Giovanni MD, PhD, Ugo MD, PhD, Caterina MD, PhD, Vitantonio MD, Maria F. PhD, Mario MD,